Lilly's 15th Buyout of 2026 Is Up to $1.5B for Blood Cancer Startup

Eli Lilly has agreed to buy Calytrix Bio, a private biotech in Wellesley, Massachusetts, for up to $1.5 billion in cash. Calytrix announced the deal on Nov. 16. Its work targets myelofibrosis and essential thrombocythemia, two rare, slow-growing blood cancers.
What happened
Calytrix said Lilly will pay its shareholders an upfront sum, plus more cash if the program reaches certain clinical and regulatory milestones. Calytrix did not disclose the upfront amount, BioPharma Dive reported. The milestones were not described either.
Calytrix was formed in 2025 by J.P. Morgan Life Sciences Private Capital, the venture arm of J.P. Morgan Asset Management. Westlake BioPartners and Avoro Ventures also invested. BioPharma Dive described the company as stealthy before the deal. Brad Prosek is its president and chief executive.
The lead program is a biparatopic antibody. That means it latches onto one protein at two different places. The target is mutant calreticulin, or mutant CALR. The company said the antibody binds both Type 1 and Type 2 mutant forms, which sit on the surface of the diseased cells. The aim is to remove the cells that drive the disease while sparing healthy tissue. Calytrix called it a preclinical program, so it has not yet been tested in people.
Why it matters
BioPharma Dive counted this as Lilly's 15th company acquisition announced this year. It reported that Lilly has spent more than $30 billion on those 15 deals, most of them for private startups. By comparison, GSK, Gilead and Novartis had each bought three drug companies in 2026, the outlet said. Pharmaceutical Technology called Lilly the busiest dealmaker in big pharma so far this year.
The deal also shows how much large companies will pay for early science. Calytrix has shared no clinical data, yet the deal could reach $1.5 billion if every milestone is met.
For patients, current options for these cancers include transfusions and JAK inhibitors such as Incyte's Jakafi. Calytrix says those treatments mainly manage symptoms and complications. Its stated goal is a therapy that acts on the disease itself. That remains unproven until human trials run.
What it means for people in the industry
The sources did not say what happens to Calytrix staff or its Massachusetts site after the deal closes. They also gave no closing date. Things to watch include the closing date and when Lilly moves the antibody into its first human trial.
For people in early drug discovery, the deal is one more sign that big pharma is buying young private biotechs, often before any human data exist.
See open pharma jobs in the US and Canada
Sources
- Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis, PR Newswire (Calytrix Bio)
- Lilly adds to buyout streak with $1.5B purchase of startup Calytrix, BioPharma Dive (via Yahoo Finance)
- Lilly agrees to acquire Calytrix Bio for $1.5bn, Pharmaceutical Technology
Check Your Supplement Interactions
Use our AI-powered checker to analyze supplement safety and interactions.
Open Interaction Checker →Comments (0)
This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.